Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$33.16 USD
+2.66 (8.72%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $33.15 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Xenon Pharmaceuticals Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
XENE 33.16 +2.66(8.72%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Other News for XENE
Xenon Pharmaceuticals Inc (XENE) Announces Upcoming Q2 2025 Financial Results and Business ...
Xenon to Report Q2 2025 Financial Results on August 11, 2025 | XENE Stock News
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE ...
Xenon Pharmaceuticals Inc (XENE) Announces Equity Inducement Grants | XENE stock news
BlackRock, Inc. Expands Stake in Xenon Pharmaceuticals Inc.